Article Details

Lilly Announces FDA Approval for Lebrikizumab-lbkz of Moderate to Severe Atopic Dermatitis

Retrieved on: 2024-09-16 16:31:35

Tags for this article:

Click the tags to see associated articles and topics

Lilly Announces FDA Approval for Lebrikizumab-lbkz of Moderate to Severe Atopic Dermatitis. View article details on hiswai:

Excerpt

The IL-13 inhibitor is indicated for treatment of adults and of pediatric patients who weigh at least 88 pounds (40 kg) and can be used with or ...

Article found on: www.patientcareonline.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up